🇺🇸 FDA

Company profile · Sponsor

Baxalta

Baxalta Innovations GmbH

EFC0478 · EMA pharma Wien, AT
Pipeline
3
Drugs
0
Patents
0

Quick answer

Baxalta (EFC0478) is a pharma company. headquartered in Wien, AT. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EFC0478
Exchange EMA
Company type pharma
Headquarters Wien, AT

Pipeline (3)

Search pipeline →

  1. RECOMBINANT ADAMTS13 (rADAMTS13), RECOMBINANT ADAMTS13 (rADAMTS13)

    Baxalta

    Congenital Thrombotic thrombocytopenic purpura (cTTP)

    phase 3 small molecule active

    1 trial

  2. TAK-881

    Baxalta

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  3. VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection., ADVATE 500 IU powder and solvent for solution for injection.

    Baxalta

    Hereditary severe von Willebrand Disease in children

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Baxalta?

Baxalta (EFC0478) is a pharma company. headquartered in Wien, AT. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Baxalta sponsor?

We track 3 ClinicalTrials.gov-linked programs for Baxalta, including RECOMBINANT ADAMTS13 (rADAMTS13), RECOMBINANT ADAMTS13 (rADAMTS13) and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Baxalta company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.